Solid Biosciences says interim results reinforce confidence in SGT-003 potential [Yahoo! Finance]
Solid Biosciences Inc. (SLDB)
Last solid biosciences inc. earnings: 8/14 07:25 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.solidbio.com/investor-relations
Company Research
Source: Yahoo! Finance
Solid Biosciences ( SLDB ) reported updated “positive” interim data from the ongoing Phase 1/2 INSPIRE DUCHENNE clinical trial of SGT-003. The new data, including additional muscle biopsy, serum biomarker, cardiac function, and safety analyses, “add to a growing dataset that suggests the potential of the biological activity of SGT-003 microdystrophin therapy,” the company stated. The interim update was delivered in an oral presentation at the 2026 MDA Annual Meeting on March 11. “SGT-003 has been generally well tolerated in the 40 participants dosed as of March 11, 2026. The safety and tolerability profile observed in the INSPIRE DUCHENNE trial continued to be promising; SGT-003 is administered using a low-burden, steroid-only prophylactic immunomodulation regimen. The trial is being conducted at 15 clinical sites across the US, Canada, Italy and the United Kingdom and participant dosing remains ongoing. Microdystrophin transduction and expression levels, beta-sarcoglycan localizatio
Show less
Read more
Impact Snapshot
Event Time:
SLDB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLDB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLDB alerts
High impacting Solid Biosciences Inc. news events
Weekly update
A roundup of the hottest topics
SLDB
News
- Solid Biosciences (SLDB) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
- Solid Biosciences (SLDB) had its price target raised by JPMorgan Chase & Co. from $11.00 to $12.00. They now have an "overweight" rating on the stock.MarketBeat
- Solid Biosciences (SLDB) had its "buy" rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Solid Biosciences (SLDB) is now covered by Guggenheim. They set a "buy" rating and a $26.00 price target on the stock.MarketBeat
- Solid Biosciences (SLDB) had its "buy" rating reaffirmed by Chardan Capital. They now have a $15.00 price target on the stock.MarketBeat
SLDB
Earnings
- 3/19/26 - Miss
SLDB
Sec Filings
- 3/19/26 - Form S-3
- 3/19/26 - Form S-3
- 3/19/26 - Form S-8
- SLDB's page on the SEC website